Cargando…
Tocilizumab overcomes chemotherapy resistance in mesenchymal stem-like breast cancer by negating autocrine IL-1A induction of IL-6
Triple-negative breast cancer (TNBC) patients with mesenchymal stem-like (MSL) subtype have responded poorly to chemotherapy whereas patients with basal-like 1 (BL1) subtype achieved the best clinical response. In order to gain insight into pathways that may contribute to the divergent sensitivity t...
Autores principales: | Chung, Andrew W., Kozielski, Anthony J., Qian, Wei, Zhou, Jianying, Anselme, Ann C., Chan, Alfred A., Pan, Ping-Ying, Lee, Delphine J., Chang, Jenny C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904846/ https://www.ncbi.nlm.nih.gov/pubmed/35260569 http://dx.doi.org/10.1038/s41523-021-00371-0 |
Ejemplares similares
-
The Cytokine IL-17A Limits Th17 Pathogenicity via a Negative Feedback Loop Driven by Autocrine Induction of IL-24
por: Chong, Wai Po, et al.
Publicado: (2020) -
Autocrine IL-6 mediates pituitary tumor senescence
por: Sapochnik, Melanie, et al.
Publicado: (2016) -
Autocrine IL-17A–IL-17RC neutrophil activation in fungal infections is regulated by IL-6, IL-23, RORγt and Dectin-2
por: Taylor, Patricia R., et al.
Publicado: (2013) -
Tocilizumab Induces IL-10-Mediated Immune Tolerance in Invasive Candidiasis
por: Tan, Zhaohong, et al.
Publicado: (2021) -
Tocilizumab Improves the Prognosis of COVID-19 in Patients with High IL-6
por: Flisiak, Robert, et al.
Publicado: (2021)